创新药研发，需以源头创新为驱动

Group 1 - The core viewpoint highlights the rapid development of China's innovative drug industry, with nearly 40 first-class innovative drugs approved in the first half of the year, approaching last year's total of 48 [1] - The total amount of overseas licensing transactions for innovative drugs reached $45.5 billion in the first five months, with a record-breaking upfront payment from a domestic company [1] - The growth of the innovative drug sector is attributed to high investment in technological innovation by pharmaceutical companies and strong policy support, including reforms in drug review and approval systems [1][2] Group 2 - The transition from "follow-up innovation" to "source innovation" requires a dual approach of scientific and industrial innovation, focusing on new mechanisms and treatment strategies in drug research [2] - Successful case studies, such as a 160 million yuan transaction between a university and a pharmaceutical company, demonstrate the potential of unique discoveries in drug development [2] - To foster "source innovation," it is essential to create a supportive ecosystem for innovative drug development, including increased investment in early-stage companies and a fair pricing mechanism reflecting R&D costs [2] Group 3 - The essence of innovative drugs lies in innovation, supported by technological advancements, patient capital, and favorable policies, which can significantly enhance the development of domestic innovative drugs [3]